Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

• Number of Adverse Event as a measure of safety and tolerability of AZD3839 (Part 1) [ Time Frame: Part 1 - AEs will be collected from admission to the study centre (Visit 2, Day-1) until the follow-up visit (Visit 3) approximately 15 days ] [ Designated as safety issue: Yes ]
• Number of Adverse Events as a measure of Safety and tolerability of AZD3839 (Part 2) [ Time Frame: Part 2 - AEs will be collected from admission to the study centre (Visit 2, Day-1) until the follow-up visit (Visit 4) approximately 20 days ] [ Designated as safety issue: Yes ]

• Time at which maximum concentration occurs in AZD3839 (Part 1) [ Time Frame: pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 56 and 72 hours after the administration of the investigational product, as well as on Day 4 and at the follow-up visit (Visit 3) ] [ Designated as safety issue: No ]
• Maximum observed concentration of AZD3839 in plasma (Part 1) [ Time Frame: Part 1 - pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 56 and 72 hours after the administration of the investigational product, as well as on Day 4 and at the follow-up visit (Visit 3) ] [ Designated as safety issue: No ]
• Time at which maximum concentration occurs in AZD3839 (Part 2) [ Time Frame: Part 2 - at pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 56 and 72 hours after the Administration. May be taken at the follow-up visit (Visit 4) ] [ Designated as safety issue: No ]
• Maximum observed concentration of AZD3839 in plasma (Part 2) [ Time Frame: Part 2 - at pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 56 and 72 hours after administration ] [ Designated as safety issue: No ]

• Time at which maximum concentration occurs in AZD3839 [ Time Frame: 20 Days from Visit 1 to follow-up ] [ Designated as safety issue: No ]
• Maximum observed concentration of AZD3839 in plasma [ Time Frame: 20 Days from Visit 1 to follow-up ] [ Designated as safety issue: No ]

The purpose of the study is to assess the safety, tolerability and blood concentration of AZD3839 following oral administration of single doses in healthy men and women of non-childbearing potential

• Alzheimer's Disease
• Safety
• Tolerability
• Blood Concentration
• Healthy Volunteers

• Drug: AZD3839
  Single Oral Dose
• Drug: AZD3839 Placebo
  Single Oral Dose

• Experimental: AZD3839
  Oral Treatment
  Intervention: Drug: AZD3839
• Placebo Comparator: AZD3839 Placebo
  Oral Treatment
  Intervention: Drug: AZD3839 Placebo

Inclusion Criteria:

• Healthy male and female volunteers of non-childbearing potential aged 18 to 55 years (inclusive) with suitable veins for cannulation or repeated venipuncture
• Have a body mass index (BMI) between 19 and 30 kg/m2 (inclusive) and weigh between 50 kg and 100 kg (inclusive)
• Creatinine clearance in the normal range (>80 mL/min estimated according to Cockroft-Gault)
• Healthy volunteers should have a serum potassium concentration of ≥3.8 mmol/L at screening (Visit 1) and on admission to the study centre (Day -1)
• Clinically normal findings on physical examination in relation to age, as judged by the Investigator

Exclusion Criteria:

• History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the healthy volunteer at risk because of participation in the study, or influence the results or the healthy volunteer's ability to participate in the study
• History of psychotic disorder amongst first degree relatives
• Significant orthostatic reaction at enrolment as judged by the Investigator
• Prolonged QTcF greater than 450 msec or shortened QTcF less than 340 msec or family history of long QT syndrome or sudden death
• Healthy volunteer is a vegetarian/lactose intolerant (exclusion criterion only applicable for healthy volunteers participating in Part 2